Does Naltrexone Block Adderall Effects?

Naltrexone dulls the subjective “high” from amphetamines like Adderall, but it does not appear to strip away the symptom-control benefits that make these medications useful for ADHD. The reason for this split is that naltrexone and amphetamine act on different primary brain systems, and their interactions are more layered than a simple cancellation. Whether you are taking both drugs simultaneously or wondering about a future prescription, the details of what naltrexone actually does and does not block are worth knowing.

What Naltrexone Does to the Amphetamine Experience

Naltrexone is an opioid receptor blocker, originally approved to help people with alcohol or opioid dependence. It works by occupying the same receptors that endorphins use, preventing those feel-good signals from getting through. Amphetamines like Adderall work primarily on a different system: they boost dopamine and norepinephrine. But the opioid and dopamine systems talk to each other, and that crosstalk is where things get interesting.

In controlled human studies, naltrexone significantly reduces the subjective effects of amphetamine. People report feeling less of the rush, less euphoria, and less of the overall “drug effect” when they have naltrexone on board before taking an amphetamine dose. One study comparing naltrexone pretreatment to placebo found a large and statistically significant reduction in how strong the amphetamine felt to participants.¹ Research in amphetamine-dependent patients has replicated this: naltrexone blocked the craving triggered by a dexamphetamine dose and significantly reduced the subjective high, even in people with established tolerance to amphetamines.²

What naltrexone does not seem to touch, however, are the cardiovascular and physiological effects of amphetamine. Heart rate, blood pressure, and other body-level responses to amphetamine look roughly the same whether naltrexone is present or not.² This tells us something important: naltrexone is not shutting down the amphetamine broadly. It is targeting something more specific, likely the opioid-mediated reward layer that sits on top of the core dopamine-driven stimulant response.

Why Dopamine Still Surges Despite Opioid Blockade

If naltrexone reduces how high amphetamine makes you feel, you might assume it is blocking dopamine release. It is not. Brain-imaging studies in humans and parallel experiments in rats have shown that after a single amphetamine dose, dopamine levels in the striatum rise substantially whether naltrexone is present or absent. There is no statistically significant difference in dopamine output between the naltrexone-plus-amphetamine and placebo-plus-amphetamine conditions in the acute setting.¹

This creates a genuine puzzle. Naltrexone changes how amphetamine feels without changing the dopamine flood that supposedly creates those feelings. The most likely explanation is that the subjective high from amphetamine is not purely a dopamine story. Part of what makes the rush feel rewarding involves the brain’s endogenous opioid system: endorphins and enkephalins that get released in response to the dopamine surge. Naltrexone blocks those opioid receptors, so the opioid component of the reward experience gets muted even while the dopamine component rolls on as usual. Research looking at brain reward networks supports this interpretation, suggesting that naltrexone’s therapeutic effects reflect changes in how the basal ganglia manage attention and reward processing, not a direct suppression of reward chemistry.³

The picture shifts when amphetamine exposure is chronic. In animal studies where rats received daily amphetamine for ten days followed by a drug-free washout period and then a challenge dose, naltrexone pretreatment cut the amphetamine-driven dopamine elevation by roughly half.⁴ Chronic stimulant use reshapes the relationship between the opioid and dopamine systems in a way that makes naltrexone’s blockade more consequential at the dopamine level. For someone who has been taking Adderall daily for months or years, the dynamics may differ from what a single-dose laboratory study reveals, though human data on this specific question remain limited.

ADHD Symptom Control Is Not Compromised

This is the question that matters most to people taking Adderall for ADHD who need or want naltrexone for a separate condition. A double-blind, placebo-controlled trial directly tested whether adding naltrexone to methylphenidate (a closely related stimulant) would undermine ADHD treatment. Over six weeks of combined use, naltrexone did not interfere with the clinical effectiveness of the stimulant for ADHD symptoms. Scores on a standard ADHD rating scale were statistically indistinguishable between the naltrexone group and the placebo group, and dropout rates were nearly identical.⁵ The combination also did not produce more side effects than the stimulant alone.

This fits the neurochemistry. ADHD symptom relief from stimulants is driven by increased dopamine and norepinephrine in prefrontal circuits that govern attention, working memory, and impulse control. Since naltrexone leaves dopamine release largely intact in the acute setting, the therapeutic action of the stimulant continues. What gets reduced is the euphoric overlay, not the cognitive benefit. For people whose ADHD medication sometimes produces an unwanted sense of being “wired” or artificially elated, naltrexone may even take the edge off that feeling without sacrificing focus and executive function.

Euphoria During the Dose-Adjustment Window

There is one notable timing wrinkle. A separate placebo-controlled trial found that naltrexone significantly reduced the euphoric effect of methylphenidate during the first three weeks of treatment, when the stimulant dose was still being increased. But during the maintenance phase from weeks four through six, naltrexone’s dampening effect on euphoria was no longer statistically significant.⁶

This pattern makes sense. During titration, each dose increase can produce a small spike in subjective reward before the brain adapts. Naltrexone appears to blunt that spike. Once the stimulant dose stabilizes and the brain adjusts, there is less of an acute euphoric component to block. If you are starting or adjusting your Adderall dose while already on naltrexone, you might notice less of an initial buzz than you would otherwise, but this does not seem to affect long-term symptom control.

Naltrexone as a Treatment for Amphetamine Addiction

A very different clinical population is relevant here: people who misuse amphetamines. For this group, the question is not whether naltrexone ruins the therapeutic effect but whether it can help reduce compulsive use. The evidence points cautiously in that direction. A randomized, placebo-controlled trial of naltrexone for amphetamine dependence found significant reductions in both craving levels and self-reported amphetamine consumption in the naltrexone group compared to placebo.⁷

The logic tracks with the subjective-effects data: if naltrexone makes amphetamine feel less rewarding, the incentive to seek it out decreases. The fact that it dials down craving while leaving physiological stimulant effects largely intact suggests its benefit in addiction is more about removing the pleasure signal than about making the drug pharmacologically inert. This is a different mechanism than, say, using naltrexone for opioid dependence, where the drug genuinely blocks opioids from producing their primary effect. With amphetamines, naltrexone is peeling away a secondary reward layer rather than disabling the drug’s core action.

Combining Naltrexone With Bupropion for Methamphetamine Disorder

The most clinically advanced use of naltrexone in stimulant addiction pairs it with bupropion, an antidepressant that also has mild dopamine and norepinephrine activity. A large randomized trial published in the New England Journal of Medicine tested injectable extended-release naltrexone plus daily oral bupropion against placebo in people with methamphetamine use disorder. The combination produced a response rate of about 14%, compared with roughly 3% for placebo, a statistically significant difference.⁸ An earlier pilot study using the same combination had shown a higher response rate of about 24%.⁹

These numbers are modest, and researchers have acknowledged that response rates remain suboptimal, with only about one in six participants achieving a defined response in initial treatment.¹⁰ But methamphetamine use disorder has been notoriously difficult to treat with medications, and naltrexone-bupropion is one of the first combinations to show a clear edge over placebo in large trials. The fact that naltrexone alone does not shut down dopamine release may be exactly why bupropion is added: bupropion provides a small dopaminergic replacement effect while naltrexone strips away the opioid-mediated reward, and together they address two different components of the addiction cycle.

Behavioral Effects That Naltrexone Does Not Touch

One area where naltrexone’s limits become especially clear is in self-administration and choice behavior. In a study using both rhesus monkeys and rats, naltrexone did not change how much amphetamine the animals chose to take when given the option of amphetamine versus food. Amphetamine maintained dose-dependent self-administration patterns regardless of naltrexone pretreatment, and total amphetamine intake was unaffected.¹¹ Males chose more amphetamine overall than females, but naltrexone did not alter this pattern in either sex.

This is a somewhat uncomfortable finding for the addiction treatment narrative. If naltrexone reduces how good amphetamine feels but does not change how much animals choose to take, the relationship between subjective pleasure and drug-seeking behavior is not as straightforward as it might seem. One possibility is that amphetamine’s reinforcing properties operate partly through dopamine pathways that naltrexone does not reach. Another is that the animal choice models do not fully capture the more complex decision-making and craving responses that occur in humans. Either way, the gap between reduced subjective effects and persistent self-administration is a reminder that blocking the high does not automatically solve the behavioral problem.

Similarly, animal research on locomotor effects has shown mixed results. In one study, naltrexone reduced the rearing behavior triggered by amphetamine in a dose-dependent manner, but had no effect on locomotor activity, and this pattern held across repeated dosing.¹² Rearing is often interpreted as an exploratory or reward-seeking behavior, while forward locomotion reflects more general arousal. The selective reduction in one but not the other echoes the broader theme: naltrexone trims specific reward-related behaviors without disabling the stimulant’s general activating effects.

Sleep Disruption From Stimulants

A recent study in male rhesus monkeys looked at whether naltrexone could counteract the sleep problems caused by methamphetamine, and the results were striking. Methamphetamine significantly increased how long it took to fall asleep, increased the amount of time spent awake after initially falling asleep, and decreased overall sleep efficiency. Evening treatment with naltrexone improved all three of these measures in a dose-dependent fashion, with the highest dose producing significant improvements across the board.¹³

This finding opens an intriguing angle. Many people on stimulant medications experience difficulty sleeping, and if naltrexone can rescue sleep architecture without undermining daytime symptom control, the combination could have practical value beyond its current clinical uses. The mechanism probably involves naltrexone dampening the stimulant’s activation of opioid-mediated arousal pathways, which are distinct from the dopamine-driven wakefulness that stimulants produce. To be clear, this has been demonstrated in monkeys with methamphetamine, not in humans with prescribed Adderall, so it is far from a clinical recommendation. But it is a direction that researchers are actively exploring.

What This Means If You Take Both Drugs

People most often find themselves on both naltrexone and a stimulant in one of two scenarios. The first is someone being treated for ADHD with Adderall or a similar medication who also takes naltrexone for alcohol use disorder. The second is someone in addiction treatment who takes naltrexone and either still uses stimulants or is being prescribed them for a co-occurring condition. In either case, the available evidence suggests that naltrexone will reduce the euphoric component of the stimulant without undermining its therapeutic effects for attention and executive function. The combination does not appear to create new safety concerns beyond what each drug produces on its own.

The one caveat worth noting is the chronic-use finding from animal research: when amphetamine exposure is sustained over time and followed by a gap, naltrexone’s ability to suppress dopamine release increases substantially. Whether this translates to a meaningful clinical effect in people taking daily Adderall over months or years is unknown. It is possible that naltrexone’s neurochemical interaction with amphetamine deepens with long-term use in ways that have not been captured by the relatively short human trials conducted so far. If you are on both medications and notice changes in how your stimulant feels over time, that finding is worth discussing with your prescriber, though it is not a reason to avoid the combination based on current evidence.

The broader takeaway from the research is that naltrexone and amphetamines operate on parallel but interconnected tracks. Blocking opioid receptors strips away one layer of the stimulant experience, the rewarding rush, while leaving the dopaminergic engine that drives cognitive enhancement largely untouched. For ADHD treatment, that is reassuring. For addiction treatment, it is a start but clearly not enough on its own, which is why the combination with bupropion has emerged as the more promising clinical strategy.